Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Lifitegrast

SKU: orb1227126

Description

A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG; development as an ophthalmic solution for treating dry eye.Other Indication Approved(In Vitro):Lifitegrast (SAR 1118) inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses.Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM.\n(In Vivo):Lifitegrast (SAR 1118), has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior.Lifitegrast (SAR 1118) ophthalmic drops administered thrice daily deliver therapeutic levels of Lifitegrast (SAR 1118) in the retina and can alleviate the retinal complications associated with diabetes.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number1025967-78-5
MW615.4811
Purity>98% (HPLC)
FormulaC29H24Cl2N2O7S
SMILESO=C(O)[C@@H](NC(C1=C(Cl)C2=C(CN(C(C3=CC=C4C=COC4=C3)=O)CC2)C=C1Cl)=O)CC5=CC=CC(S(=O)(C)=O)=C5
TargetIntegrin
SolubilityDMSO: ≥ 29 mg/mL

Bioactivity

In Vivo
Lifitegrast (SAR 1118), has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior. Lifitegrast (SAR 1118) ophthalmic drops administered thrice daily deliver therapeutic levels of Lifitegrast (SAR 1118) in the retina and can alleviate the retinal complications associated with diabetes.
In Vitro
Lifitegrast (SAR 1118) inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses. Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

SAR1118 | SAR 1118 | SAR-1118

Similar Products

  • Lifitegrast [orb1303486]

    99.66% (May vary between batches)

    1025967-78-5

    615.48

    C29H24Cl2N2O7S

    100 mg, 5 mg, 25 mg, 10 mg, 50 mg, 500 mg, 1 ml x 10 mM (in DMSO)
  • Lifitegrast sodium [orb1691063]

    99.33% (May vary between batches)

    1119276-80-0

    637.46

    C29H23Cl2N2NaO7S

    5 mg, 1 mg
  • Lifitegrast impurity 6 [orb3181197]

    1270093-99-6

    243.28

    C10H13NO4S

    50 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

5 mg
$ 80.00
10 mg
$ 100.00
25 mg
$ 160.00
50 mg
$ 270.00
100 mg
$ 430.00
500 mg
$ 1,030.00